Merck's hep C combo hits cure-rate goal in IV drug users; Meda's Elidel could suffer on Valeant pharmacy snafu;

> Merck & Co.'s ($MRK) forthcoming hepatitis C regimen got a boost from new data showing that it delivered a high cure rate in patients who use intravenous drugs, the "hot core" of people with the disease. Report

> Sweden's Meda, whose dermatology drug Elidel is licensed in the U.S. to Valeant Pharmaceuticals ($VRX), could see sales disruptions from its partner's specialty pharmacy woes. Report

> Gilead Sciences ($GILD) won expanded FDA approval for its blockbuster hepatitis C combo pill Harvoni, extending use to new subtypes of hep C and to patients co-infected with HIV. Report

And Finally... Professional cycling's Team Novo Nordisk met with Pope Francis for World Diabetes Day last week. Report